Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

478 output Results for «Cancer»

ReviewOpen (repository)202613citation· Semantic Scholar

Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials

Food Science & Nutrition · vol. 14 (2) · e71452-e71452

(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.

curcuminoidscurcuminanticancer mechanismMAPK signaling
ArticleOpen access20265citation· Semantic Scholar

Phytochemical Characterisation, antioxidant, anti-inflammatory, antibacterial, antibiofilm, anticancer properties and therapeutic potentials of Eucalyptus globulus essential oil

Scientific Reports · vol. 16 (1)

The Eucalyptus globulus essential oil (EGEO) is widely recognized for its pharmacological relevance; however, comprehensive evaluation of its phytochemical composition and bioactivities remains limited. In this study, EGEO was extracted from fresh leaves via hydro-distillation and characterized using GC-MS, LCMS, FTIR, and UV-Visible spectroscopy. Qualitative screening confirmed the presence of key secondary metabolites, including triterpenoids, flavonoids, phenols, steroids. Quantitative analysis revealed high levels of total phenolics (65.12 ± 0.01 mg GAE/g) and flavonoids (57.75 ± 0.01 mg QE/g). The oil exhibited concentration-dependent antioxidant activity in the DPPH assay with an IC₅₀ value of 604.01 µl/mL, indicating potent radical-scavenging ability. Anti-inflammatory assessment through protein denaturation and human red blood cell (HRBC) membrane stabilization assays demonstrated moderate inhibitory and cytoprotective effects comparable to standard drugs. EGEO also showed strong antibacterial efficacy against Tannerella forsythia, Prevotella intermedia and Aggregatibacter with inhibition zones of 19-25 mm while showed notable antibiofilm activity against T. forsythia. Cytotoxic evaluation indicated selective action, showing minimal toxicity toward normal L929 fibroblasts and moderate inhibition of B16F10 melanoma cells. Overall, these findings suggest that Eucalyptus globulus essential oil is a rich source of bioactive phytoconstituents with potential therapeutic applications as a natural antioxidant, anti-inflammatory, antibacterial, antibiofilm, and anticancer agent.

Eucalyptus globulusessential oilsphytochemical compositionantioxidant activity
ArticleClosed20264citation· Semantic Scholar

Folate-functionalized chitosan nanoparticles: a versatile platform for targeted drug delivery and biomedical applications

International Journal of Polymeric Materials · vol. 75 (8) · 835-858

Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanopreci­pitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.

targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
ReviewOpen access20263citation· Semantic Scholar

From mechanism to medicine: CRISPR‒Cas9 delivery strategies, therapeutic applications and translation challenges

Discover Nano · vol. 21 (1)

The advent of CRISPR‒Cas technology has revolutionized genome editing by providing unprecedented precision, efficiency, and versatility in genetic manipulation. This revolutionary system originated from bacterial adaptive immunity. It allows the programmed modification of DNA sequences in a highly specific way, as long as the desired modification site contains an enzyme-compatible protospacer adjacent motif (PAM) sequence. Recent innovations with CRISPR‒Cas systems have focused on optimizing delivery methods, addressing challenges and expanding their therapeutic applications. Delivery approaches, including viral vectors, lipid nanoparticles, and other nonviral vectors, have been improved to increase target specificity while minimizing off-target effects, ensuring safe and efficient In Vivo genome editing. The applications of CRISPR‒Cas technology include the correction of genetic disorders, engineering of immune cells for cancer therapy, and combating viral infections. However, significant challenges in the form of unintended edits, immune responses, and delivery to specific tissues or organs remain formidable barriers to clinical translation. New CRISPR variants, such as base editing, prime editing, and epigenome editing, provide solutions to improve accuracy and broaden intervention. This review covers recent progress in various CRISPR delivery methodologies, discusses broadening therapeutic applications, highlights ongoing challenges, and describes the future trajectory of this disruptive technology.

CRISPR/Cas9genome editinggene deliveryviral vectors
ReviewClosed20262citation· Semantic Scholar

USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends

Archiv der Pharmazie · vol. 359 (6) · e70272-e70272

Small-molecule-based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near-universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3- or 4-membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A-mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug-discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.

FDA-approved drugsnew chemical entitiessmall molecule drugsdrug discovery
ArticleOpen access20261citation· Semantic Scholar

Retinoblastoma Incidence in Saudi Arabia: A 20-Year Analysis

Asian Pacific Journal of Cancer Prevention · vol. 27 (8) · 2853-2860

BACKGROUND: Retinoblastoma (Rb) represents the most frequent primary intraocular cancer in the pediatric population; yet comprehensive national data are limited in Saudi Arabia due to incomplete cancer registry coverage and underreporting. The present study systematically investigates the incidence, distribution, and trends of retinoblastoma across Saudi Arabia over two decades, utilizing robust data from the Saudi National Cancer Registry (SCR), a nationwide surveillance system overseen by the Ministry of Health. METHODS: This retrospective population-based analysis included all children diagnosed with Rb in Saudi Arabia between January 1, 2000, and December 31, 2019. The study examined incidence rates and temporal patterns by age, regional location, and tumor histology. RESULTS: Out of 542 documented cases (258 females, 284 males), the age-standardized incidence rate (ASIR) for children aged 0-4 years demonstrated an initial increase, peaking at 1.26 per 100,000 in 2003, followed by a gradual decline to 0.93 per 100,000 by 2019. Higher incidence rates were detected in major urban centers, especially Riyadh and Makkah, likely reflecting demographic density, enhanced diagnostic practices, and more accessible specialized care. Most tumors were either undifferentiated (Grade IV) or not otherwise specified (NOS, 63%), while diffuse retinoblastoma was rare (2%). Diagnosis was predominantly confirmed by histopathological evaluation (88.3%). CONCLUSION: This study offers the most comprehensive picture to date of retinoblastoma incidence and patterns in Saudi Arabia. The observed rising incidence, together with regional disparities, emphasizes the need for more refined cancer surveillance, equitable resource allocation, and accelerated early detection strategies, particularly in underserved areas. These findings provide essential baseline metrics to inform national cancer control policies and optimize equitable resource distribution.

retinoblastomapediatric cancer incidenceSaudi Arabiaage-standardized incidence rate
ArticleOpen access20261citation· Semantic Scholar

Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis

Health Economics Review · vol. 16 (1)

BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.

dostarlimabendometrial cancercarboplatin-paclitaxelcost-utility analysis
ArticleOpen access20261citation· Semantic Scholar

Optimized collagenase biosynthesis (Bacillus siamensis strain Z1) and its application in collagen hydrolysate-mediated silver and zinc oxide nanoparticles synthesis and characterization with antibacterial, antioxidant and cytotoxic activities

PLoS ONE · vol. 21 (3) · e0344482-e0344482

Globally, environmental pollution caused by resilient protein like collagen is escalating due to inefficient disposal practices. Accumulation of collagen waste poses ecological threat, necessitating management strategies. Current study discloses collagenolytic bacterium, Bacillus siamensis strain Z1, isolated from marine water (Goa) demonstrating collagen breakdown and inducing collagenase biosynthesis. Production kinetics revealed optimal collagenase production (4.55 U/mL) on 2nd day with a protein content of 0.69 mg/mL. Influence of physiochemical parameters, including inoculum size, metal ions, carbon and nitrogen sources, pH and temperature on collagenase yield was optimized achieving 17.93 folds enhancement by central composite design. Silver (AgNP) and Zinc oxide (ZnONP) nanoparticles were biosynthesized using collagen hydrolysate derived from marine collagen through collagenase action and characterized using UV-Visible spectroscopy, Fourier Transform Infrared Spectroscopy, X-ray Diffraction, Scanning Electron Microscopy with Energy Dispersive X-ray, Thermogravimetric Analysis and Atomic Force Microscopy elucidated thermostability, structure and surface characteristics. Antibacterial effect of nanoparticles was observed against B. cereus and E. coli. AgNP and ZnONP demonstrated antioxidant properties assessed by ABTS and DPPH assays. AgNP and ZnONP exhibited cytotoxicity on MCF-7 breast cancer cell lines, with IC50 values 8.87 µg/mL and 25.21 µg/mL respectively. The study highlights biotechnological potential of collagenase in generating bioactive products for therapeutical and biomedical advancements.

Bacillus siamensiscollagen peptidessilver nanoparticleszinc oxide nanoparticles